Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

Trial Profile

A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; SX 682 (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Syntrix Biosystems
  • Most Recent Events

    • 20 Jun 2019 According to a Syntrix Biosystems media release, the company has dosed the first patient in this clinical study. The company expects to report initial clinical data from the trial in the first half of 2020.
    • 14 Jan 2019 Status changed from not yet recruiting to recruiting.
    • 20 Nov 2018 Planned initiation date changed from 1 Oct 2018 to 15 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top